breast cancer

David Cortez, Ph.D., and his Vanderbilt colleagues report new findings that shed light on fundamental processes involved in DNA replication and have implications for cancer therapies that target these processes.

A group of Vanderbilt researchers has used laser technology and a custom-built multiphoton microscope to distinguish breast cancer subtypes and determine if specific therapies are working against the cancer cells in as little as two days.

Vanderbilt-Ingram Cancer Center investigators are receiving $1 million in breast cancer research grant funds from Susan G. Komen, the largest nonprofit foundation supporting breast cancer research.

Researchers are developing imaging methods to predict patient outcome early in the course of chemotherapy for breast cancer – to allow clinicians to adjust therapy for patients who are not responding.

Diseases associated with mutations and changes in expression of the protein caveolin may result from faulty trafficking of the protein to the cell surface.

Many patients with triple-negative breast cancer (TNBC) have recurrence of their disease after an initial response to chemotherapy because the cancer cells have become resistant to treatment. TNBC has a lower survival rate because of this pattern of resistance and there are no targeted agents to treat this form of breast cancer.

Researchers at Vanderbilt University have found a powerful new genetic risk factor for breast cancer.